Anticancer Protein
Anticancer Protein - Related Videos
01:49
An Assay To Evaluate the Anticancer Effects of Lactobacillus Cell-Free Supernatant
0 Views •
2025
This video demonstrates an in vitro assay to study the anticancer effects of Lactobacillus cell-free supernatant (LCFS). Upon exposing colorectal cancer spheroids to varying doses of LCFS, the interaction with the bacterial metabolites in LCFS induces apoptosis in the cancer cells, disrupting the spheroid structure and leading to cell death in a dose-dependent manner.
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
04:11
Colony Formation Assay: Assessing the Efficacy of Anticancer Agents on Colony-Forming Lung Cancer Cells
0 Views •
2023
This video describes the colony formation assay, which helps determine lung cancer cells' ability to proliferate indefinitely and form individual colonies. We can analyze the effect of an anticancer agent on the colony-forming cells by analyzing the changes in the number and/or size of the resulting colonies.
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
10:46
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
0 Views •
Cited by 6 •
2022
A necessary step in anticancer aptamer development is to test its binding to the target. We demonstrate a flow cytometric-based assay to study this binding, emphasizing the importance of including a negative control aptamer and cancer cells that are positive or negative for that particular...
FAQs
They can act at cell-cycle checkpoints, where regulatory decisions limit the division of abnormal cells. Other anticancer proteins promote programmed cell death, removing cells that have acquired malignant characteristics. These mechanisms are important because cancer may arise when growth control or cellular elimination fails, allowing abnormal cells to persist and multiply rather than being restrained or removed.
Protein signaling normally coordinates growth, division, survival, and interactions with surrounding cells. When these signaling systems become disrupted, cells may receive inappropriate growth-promoting signals or fail to activate protective responses. Studying the altered expression and activity of relevant proteins therefore helps clarify how tumors form and progress, while identifying signaling processes that may be targeted therapeutically.
Naturally occurring cellular regulators control processes within or between cells, whereas therapeutic antibodies are designed to recognize tumor-associated molecules. Engineered proteins can be modified for particular targeting or functional purposes. These categories differ in origin and design, but all support anticancer strategies by influencing growth signals, cellular survival, or immune recognition of malignant cells.
Researchers examine its structure, expression, and activity to determine how it functions and whether it is associated with malignant behavior. Structural information can clarify relevant molecular features, while expression studies show where and when the protein is produced. Activity measurements help connect those observations with growth control, cell removal, signaling, or immune recognition.
Their expression or activity can provide information relevant to detecting or characterizing cancer, particularly when a protein is associated with tumor-related biology. In drug development, researchers investigate whether a protein can be used directly or targeted to influence malignant cells. These studies also contribute to precision therapies by linking treatment design with tumor-associated molecular features.
Some anticancer proteins enhance the ability of the immune system to recognize malignant cells. This creates a biological connection between protein activity and the identification of abnormal tissue, rather than relying only on direct control of cell division or survival. Investigating that relationship supports therapeutic approaches that use tumor-associated molecules to improve immune detection and response.